Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
01 7Dupixent
02 3Dupixent
Main Therapeutic Indication : Immunology
Currency : USD
2019 Revenue in Millions : 2,261
2018 Revenue in Millions : 859
Growth (%) : 163
Main Therapeutic Indication : Dermatology
Currency : USD
2020 Revenue in Millions : 4,275
2019 Revenue in Millions : 2,551
Growth (%) : 68
Main Therapeutic Indication : Dermatology
Currency : USD
2021 Revenue in Millions : 5,779
2020 Revenue in Millions : 3,852
Growth (%) : 49
Main Therapeutic Indication : Immunology
Currency : USD
2022 Revenue in Millions : 9,095
2021 Revenue in Millions : 5,779
Growth (%) : 57
Main Therapeutic Indication : Immunology
Currency : USD
2023 Revenue in Millions : 11,565
2022 Revenue in Millions : 9,095
Growth (%) : 29
Main Therapeutic Indication : Dermatology
Currency : USD
2017 Revenue in Millions : 272
2016 Revenue in Millions : 0
Growth (%) : New Launch
Main Therapeutic Indication : Dermatology
Currency : USD
2018 Revenue in Millions : 890
2017 Revenue in Millions : 247
Growth (%) : 260%
Main Therapeutic Indication : Dermatology
Currency : USD
2020 Revenue in Millions : 3,226
2019 Revenue in Millions : 1,871
Growth (%) : 72
Main Therapeutic Indication : Dermatology
Currency : USD
2017 Revenue in Millions : 256
2016 Revenue in Millions : New Launch
Growth (%) : New Launch
Main Therapeutic Indication : Dermatology
Currency : USD
2018 Revenue in Millions : 922
2017 Revenue in Millions : 256
Growth (%) : 260%
LOOKING FOR A SUPPLIER?